FDA approval for SMA dosing option pulls Biogen stock lower amid weak momentum and heavy selling

Traders Union
All News
Business & Wealth
Companies
Biogen drops 3.78% today at $183.84

Highlights

BIIB faces near-term selling pressure, trading below key short- and medium-term moving averages despite maintaining a bullish long-term trend above the 200-day average.
Momentum indicators signal weak, mixed trend strength with mild oversold conditions, while the Awesome Oscillator and CCI remain neutral.
BIIB is expected to consolidate between $177.00 and $192.00 next week, with a breakout above $190 likely triggering renewed upside while sustained downside appears unlikely.

Biogen said the approval is an important step toward expanding options for people living with SMA. The company directed readers to its website for more information.

View post on X Loading...

The tweet was deleted by the author.

But we saved everything 🙂.

BIIB is trading at $183.84, sitting below the MA-20 ($185.80) and MA-50 ($184.80), but well above the MA-200 ($158.20). This structure points to short- and medium-term pressure from sellers, while the long-term trend remains bullish. The Ichimoku Kijun on D1 is at $189.53, which acts as immediate resistance. Near-term support is found at the MA-50 ($184.80) and key support at the MA-100 ($178.91). Immediate resistance is at the Kijun level ($189.53), with key resistance at the MA-20 ($185.80).

Momentum remains weak on D1, with both MACD and ADX signaling a lack of clear trend strength. RSI and Stoch RSI point to mild oversold conditions, while CCI remains neutral. BBP on D1 shows buyers briefly dominated but now points toward selling pressure intraday. Awesome Oscillator provides a neutral read, adding to the mixed momentum backdrop. In today's session, BIIB fell sharply by 3.78% after the open, reinforcing short-term volatility. Over the past week, BIIB is trading at $183.84, up from a previous weekly close of $181.46—a 1.31% gain. The price stands in the lower part of the weekly range, and weekly volatility stands at 6.63%. The week’s overall tone is one of recovery from the lows but with subdued momentum.

Looking ahead, the expected range for BIIB over the next week is $177.00 to $192.00, anchored about halfway between its 52-week low of $110.04 and high of $202.25. Based on W1 indicators—RSI (Buy), ADX (Buy), MACD (Strong Buy), and MA-50 (Buy)—the probability of a price increase is very high (more than 80%). The chance of a sustained decline is very low. The baseline scenario is for BIIB to consolidate within the projected range. The bullish scenario would see a breakout above immediate resistance near $190, opening a move toward the recent high. Conversely, a break below $178 could lead to a test of MA-100 support, but significant downside appears less likely given long-term momentum.

Previously it was reported that Biogen exhibited near-term bearish technical signals while maintaining a supportive longer-term outlook, with analysts emphasizing the potential for renewed momentum based on upcoming developments. As current market dynamics unfold, traders should watch for shifts in volatility or emerging catalysts that could prompt a decisive move in the stock’s prevailing scenario.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.